Gross Profit Comparison: Amneal Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated Trends

Pharmaceutical Giants: A Decade of Profit Trends

__timestampAmneal Pharmaceuticals, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 201444963400055402000
Thursday, January 1, 201549922600066107000
Friday, January 1, 2016597455000103402000
Sunday, January 1, 2017526178000135736000
Monday, January 1, 2018716403000245116000
Tuesday, January 1, 2019352997000108935000
Wednesday, January 1, 2020628393000156000000
Friday, January 1, 2021768973000214957000
Saturday, January 1, 2022784708000143418000
Sunday, January 1, 202382056500096265000
Loading chart...

In pursuit of knowledge

A Decade of Gross Profit Trends in Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Amneal Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have shown distinct trajectories in their gross profit margins. Amneal Pharmaceuticals has consistently outperformed Ligand, with its gross profit peaking in 2023 at approximately 820 million, marking a 82% increase from 2014. In contrast, Ligand Pharmaceuticals saw its highest gross profit in 2018, with a notable 245% increase from 2014, before experiencing fluctuations. This comparison highlights Amneal's steady growth and Ligand's volatility, reflecting broader industry trends and strategic differences. As the pharmaceutical landscape continues to shift, these insights provide valuable context for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025